|
Home >
Contract Assay
> In Vivo
Assays > Transplantation and Engraftment
Kinetics
Transplantation and Engraftment Kinetics in 5-FU Model
The 5-FU model is an excellent and well documented in vivo assay for monitoring myelosuppression (or protection) of various agents.
A common side effect following chemotherapeutic agent administration is myelosuppression leading to neutropenia. Other types of drugs may also exert various degrees of myelosuppression. 5-fluorouracil (5-FU) is a DNA replication inhibitor that kills rapidly dividing cells (including neutrophil progenitors) while sparing more quiescent cells (such as resting stem cells). The single dose administration of 5-FU to mice at 150 mg/kg causes a significant and almost immediate (within 2 days) reduction in the white blood cell, neutrophil, and femoral bone marrow cellularity. Over the next 12 days, there is an initial gradual recovery of the bone marrow progenitors followed by recovery of neutrophil cell numbers – a pattern similar to that seen in mice receiving chemotherapeutic drugs.
ReachBio can perform in vivo assays using the 5-FU model to:
-
Compare myelosuppressive effects of potential chemotherapeutic and other agents
-
Determine level of myelosuppression caused by various test compounds
-
Determine the nadir (lowest
cell count recorded post-treatment)
-
Determine number of days to reach an ANC of 0.5 x 106 /ml
-
Monitor the kinetics of cellular recovery post-treatment
-
Identify compounds that augment hematopoietic recovery
-
Stress-test compounds intended for use in immunocompromised patients
|
|
ReachBio's comprehensive service using the in vivo
5-FU model includes:
|
Please
contact us
to discuss your needs.
* ReachBio Study Directors are
highly knowledgeable and have
many years of experience in the
scientific and practical aspects
of the 5-FU model for the
assessment of transplantation
and engraftment kinetics.
|
